VIA
CRDL

Vident Investment Advisory’s Cardiol Therapeutics CRDL Stock Holding History

Vident Investment Advisory’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-146,807
Closed -$74.8K – 1247
2022
Q4 		$74.8K Buy
146,807
+1,375
+0.9% +$838 ﹤0.01% 1125
2022
Q3 		$149K Buy
145,432
+9,579
+7% +$11.7K ﹤0.01% 1037
2022
Q2 		$178K Buy
135,853
+9,696
+8% +$13.8K 0.01% 1150
2022
Q1 		$195K Buy
126,157
+73,512
+140% +$121K 0.01% 1195
2021
Q4 		$97K Buy
52,645
+2,079
+4% +$5.74K ﹤0.01% 1180
2021
Q3 		$208K Buy
+50,566
New +$183K 0.01% 1080

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
AI
AXS Investments Port Chester, New York $248M AUM 15.95% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
LNWTC
Laird Norton Wetherby Trust Company Seattle, Washington $4.58B AUM 30.77% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Vident Investment Advisory's CRDL Position: Q1 2023 in Review

Vident Investment Advisory sold out of Cardiol Therapeutics (CRDL) in Q1 2023, closing a stake of 146,807 shares — an estimated $74.8K sold.

Vident Investment Advisory first reported a position in CRDL in Q3 2021 and held it in 6 quarters. The position peaked at $208K in Q3 2021. 35 funds tracked by Wall St. Rank hold CRDL as of Q1 2023.

  • Vident Investment Advisory reported no remaining Cardiol Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Vident Investment Advisory sold 146,807 Cardiol Therapeutics shares in Q1 2023, an estimated $74.8K.
  • Vident Investment Advisory first reported a position in Cardiol Therapeutics in Q3 2021 and held it in 6 quarters.
  • Vident Investment Advisory's Cardiol Therapeutics position peaked at $208K in Q3 2021.
  • 35 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2023.

Based on Vident Investment Advisory's 13F filing for Q1 2023, filed 15 May 2023.